Inobaseru
504A.TTSE GROWTHPharmaceutical
Filed as Innovacell Inc. (2026-03–2026-08)
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating income | −¥702m | −¥636m | — | — | — |
| Ordinary income | −¥753m | −¥772m | −¥516m | −¥514m | −¥292m |
| Total assets | ¥7.5bn | ¥4.1bn | ¥2.5bn | ¥2.1bn | ¥1.2bn |
| Net assets / equity | ¥7.4bn | ¥3.6bn | ¥2.1bn | ¥1.8bn | ¥139m |
| EPS (basic) | ¥-23.5 | ¥-28.89 | ¥-19.45 | ¥-20.64 | ¥-44.74 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 1
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 60 figures · EDINET |